Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 5/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390287 | 0.91 | FURIN (0.38) | FURINROCK2KLKB1CTSLALB | |
| SCHEMBL26024621 | 0.87 | FOLH1 (0.41) | FOLH1 | |
| SCHEMBL29623561 | 0.87 | FURIN (0.40) | FURINROCK2CTSL | |
| SCHEMBL29528370 | 0.87 | FURIN (0.40) | FURINROCK2CTSL | |
| SCHEMBL30483106 | 0.86 | FURIN (0.40) | FURINROCK2KLKB1CTSL | |
| SCHEMBL25383060 | 0.83 | FURIN (0.37) | FURINALBFOLH1SIRT5SIRT2 | |
| SCHEMBL29048536 | 0.83 | FURIN (0.37) | FURINALBFOLH1SIRT5SIRT2 | |
| SCHEMBL26027087 | 0.83 | FURIN (0.40) | FURINROCK2KLKB1CTSLALB | |
| SCHEMBL23071953 | 0.82 | CASP1 (0.35) | FURIN | |
| SCHEMBL22690077 | 0.82 | CASP1 (0.35) | FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257156-A2 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4103236-B1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230021059-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | FURIN 2202/4885ROCK2 1619/4885KLKB1 2964/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | FURIN 2202/4885ROCK2 1619/4885KLKB1 2964/4885 |
| US-20230021059-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | NDC1, NCL, CD47 | FURIN 1409/4885ROCK2 1353/4885KLKB1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.